The South Korean memory chipmaker's stock erased a significant intraday rally after the company refuted a media report that it was in talks to acquire an Intel semiconductor facility in Ohio.
The Swedish B2B software provider reported a 10.8% year-over-year increase in net sales, attributing the improved profitability to the completion of its Aira separation and the launch of a new AI product.
German industrial holding company MBB raised its full-year profitability guidance after reporting a 62% surge in second-quarter adjusted EBITDA, driven by strong performance at its key subsidiaries.
London's FTSE 100 index edged lower as investor optimism from a surprise drop in UK inflation was offset by a sharp rise in crude oil prices driven by escalating geopolitical tensions in the Middle East.
Japan's benchmark Nikkei 225 index finished Wednesday's session in negative territory, weighed down by losses in transport and communication stocks despite a broader market that saw more advancers than decliners.
The pan-European STOXX 600 fell as investors weighed rising geopolitical risks in the energy market against a heavy slate of corporate earnings and upcoming central bank decisions.
The European planemaker's stock jumped after it announced a major share repurchase program and unveiled an ambitious target to nearly double its profits by 2029, signaling confidence to investors.
The UK publisher announced it is a recipient in the settlement resolving claims that AI firm Anthropic used copyrighted books to train its Claude model. Over 14,000 of the company's titles were identified in the class-action suit.
B. Riley reiterated its 'Buy' rating for Ovid Therapeutics, highlighting several upcoming clinical trial readouts and an undervalued drug platform as key drivers for potential stock appreciation.
